TROP2 ADC sac-TMT Inoratidza Basa Rinovimbisa reKurwisa Tumor muMatumbu Akasimba Akakwira

Musi wa6 Chikumi, magazini yepasi rose yezvekurapa inonzi Journal of Hematology & Oncology yakaburitsa mhedzisiro yechidzidzo chechikamu chekutanga/chipiri (KL264-01/MK-2870-001) chemushonga mutsva weTROP2 ADC sacituzumab tirumotecan (sac-TMT) semushonga mumwe chete wekurapa tumors dzakapararira munharaunda dzisingarapike kana kuti dzakapararira dzisingadi kurapwa kwakajairika.

Sacituzumab tirumotecan (sac-TMT) imushonga we antibody-drug unoumbwa ne anti-TROP2 monoclonal antibody yakabatana ne cytotoxic belotecan-derived topoisomerase I inhibitor (KL610023) kuburikidza nechinhu chitsva chinobatanidza.

Maitiro

Varwere vaiva nematumbu akasimba emunzvimbo/asina kubatwa nekenza asingakwanise kurapwa nemishonga yakajairika. Muchikamu chekutanga chedosi-kuwedzera kwehuwandu hwematumbu, varwere vaiva nematumbu akasimba emunzvimbo/asina kubatwa nekenza asingakwanise kurapwa nemishonga yakajairika. Sac-TMT yaipiwa neropa mavhiki maviri ega ega pa2 kusvika 12 mg/kg. Muchikamu chechipiri, varwere vane TNBC neHR+/HER2− cancer yemazamu vakagamuchira sac-TMT padosi dzakakurudzirwa dzekuwedzera (RDEs) dzakaonekwa muchikamu chekutanga. Zvinangwa zvikuru zvaive zvekutsvaga dosi yepamusoro inotenderwa (MTD) ye sac-TMT uye kugadzira RDEs (chikamu chekutanga) uye kuona ORR pa RECIST v1.1 neongororo yemuongorori (chikamu chechipiri). Zviitiko zvakashata zvakaongororwa pa NCI-CTCAE version 5.0.

Mhedzisiro

Varwere makumi matatu vakanyoreswa muchikamu chekutanga uye vakapihwa sac-TMT 2 mg/kg (n = 4), 4 mg/kg (n = 7), 5 mg/kg (n = 7), 5.5 mg/kg (n = 5), uye 6 mg/kg (n = 7). Varwere vashanu vaive neuturu hwakaganhurira dose: stomatitis yegiredhi rechitatu pa4, 5.5, uye 6 mg/kg; mapundu egiredhi rechitatu pa5 mg/kg; uye urticaria yegiredhi rechitatu pa6 mg/kg. MTD yaive 5.5 mg/kg uye RDEs dzaive 4 uye 5 mg/kg. Mukuwedzera kwedose yechikamu chechipiri, ORR (95% CI) yaive 34.8% (16.4%, 57.3%) muboka re4-mg/kg (n = 23) uye 38.9% (23.1%, 56.5%) muboka re5-mg/kg (n = 36) reTNBC. ORR (95% CI) yaive 31.7% (18.1%, 48.1%) yekenza yemazamu yeHR+/HER2− (n = 41).

Mhedziso

Sac-TMT yakaratidza kuchengetedzeka kunogoneka muvarwere vane bundu rakasimba risingabvisike munzvimbo yavo uye rinovimbisa kushanda kwekudzivirira bundu mukenza yemazamu yeTNBC neHR+/HER2 −. Sac-TMT iri kuongororwa muzvidzidzo zvechikamu chechitatu.

Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.

Nhamba yefoni: 4008803716

Email：myimmnet@163.com